Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy

被引:52
|
作者
Chang, Renbao [1 ]
Liu, Xudong [1 ]
Li, Shihua [2 ]
Li, Xiao-Jiang [1 ,2 ]
机构
[1] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 10010, Peoples R China
[2] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2015年 / 9卷
关键词
transgenic animal models; Huntington's disease; pathogenesis; therapy; KNOCK-IN MOUSE; NEURONAL INTRANUCLEAR INCLUSIONS; UBIQUITIN-PROTEASOME SYSTEM; MUTANT HUNTINGTIN; NEUROLOGICAL SYMPTOMS; TRINUCLEOTIDE REPEAT; REDUCES TOXICITY; CYTOPLASMIC TOXICITY; EMBRYONIC LETHALITY; TERMINAL FRAGMENTS;
D O I
10.2147/DDDT.S58470
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Huntington's disease (HD) is caused by a genetic mutation that results in polyglutamine expansion in the N-terminal regions of huntingtin. As a result, this polyQ expansion leads to the misfolding and aggregation of mutant huntingtin as well as age-dependent neurodegeneration. The genetic mutation in HD allows for generating a variety of animal models that express different forms of mutant huntingtin and show differential pathology. Studies of these animal models have provided an important insight into the pathogenesis of HD. Mouse models of HD include transgenic mice, which express N-terminal or full-length mutant huntingtin ubiquitously or selectively in different cell types, and knock-in mice that express full-length mutant Htt at the endogenous level. Large animals, such as pig, sheep, and monkeys, have also been used to generate animal HD models. This review focuses on the different features of commonly used transgenic HD mouse models as well as transgenic large animal models of HD, and also discusses how to use them to identify potential therapeutics. Since HD shares many pathological features with other neurodegenerative diseases, identification of therapies for HD would also help to develop effective treatment for different neurodegenerative diseases that are also caused by protein misfolding and occur in an age-dependent manner.
引用
收藏
页码:2179 / 2188
页数:10
相关论文
共 50 条
  • [21] Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease
    Vamos, Eniko
    Voros, Krisztina
    Zadori, Denes
    Vecsei, Laszlo
    Klivenyi, Peter
    JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (09) : 1079 - 1086
  • [22] Neuroprotective effects of probenecid in a transgenic animal model of Huntington’s disease
    Eniko Vamos
    Krisztina Voros
    Denes Zadori
    Laszlo Vecsei
    Peter Klivenyi
    Journal of Neural Transmission, 2009, 116 : 1079 - 1086
  • [23] Huntington Disease Pathogenesis and Treatment
    Dayalu, Praveen
    Albin, Roger L.
    NEUROLOGIC CLINICS, 2015, 33 (01) : 101 - +
  • [24] Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse
    Cowin, Randi-Michelle
    Roscic, Ana
    Bui, Nghiem
    Graham, Deanna
    Paganetti, Paolo
    Jankowsky, Joanna L.
    Weiss, Andreas
    Paylor, Richard
    BEHAVIOURAL BRAIN RESEARCH, 2012, 229 (02) : 308 - 319
  • [25] A Transgenic Minipig Model of Huntington's Disease
    Baxa, Monika
    Hruska-Plochan, Marian
    Juhas, Stefan
    Vodicka, Petr
    Pavlok, Antonin
    Juhasova, Jana
    Miyanohara, Atsushi
    Nejime, Tetsuya
    Klima, Jiri
    Macakova, Monika
    Marsala, Silvia
    Weiss, Andreas
    Kubickova, Svatava
    Musilova, Petra
    Vrtel, Radek
    Sontag, Emily M.
    Thompson, Leslie M.
    Schier, Jan
    Hansikova, Hana
    Howland, David S.
    Cattaneo, Elena
    DiFiglia, Marian
    Marsala, Martin
    Motlik, Jan
    JOURNAL OF HUNTINGTONS DISEASE, 2013, 2 (01) : 47 - 68
  • [26] Metformin therapy in a transgenic mouse model of Huntington's disease
    Ma, Thong C.
    Buescher, Jessica L.
    Oatis, Benjamin
    Funk, Jason A.
    Nash, Andrew J.
    Carrier, Raeann L.
    Hoyt, Kari R.
    NEUROSCIENCE LETTERS, 2007, 411 (02) : 98 - 103
  • [27] Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice
    Gil-Mohapel, Joana M.
    CNS NEUROSCIENCE & THERAPEUTICS, 2012, 18 (01) : 77 - 86
  • [28] Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models
    Cepeda, Carlos
    Levine, Michael S.
    NEUROSCIENTIST, 2022, 28 (01) : 20 - 40
  • [29] A Multi-omic Huntington's Disease Transgenic Sheep-Model Database for Investigating Disease Pathogenesis
    Mears, Emily R.
    Handley, Renee R.
    Grant, Matthew J.
    Reid, Suzanne J.
    Day, Benjamin T.
    Rudiger, Skye R.
    McLaughlan, Clive J.
    Verma, Paul J.
    Bawden, Simon C.
    Patassini, Stefano
    Unwin, Richard D.
    Cooper, Garth J. S.
    Gusella, James F.
    MacDonald, Marcy E.
    Brauning, Rudiger
    Maclean, Paul
    Pearson, John F.
    Waldvogel, Henry J.
    Faull, Richard L. M.
    Snell, Russell G.
    JOURNAL OF HUNTINGTONS DISEASE, 2021, 10 (04) : 423 - 434
  • [30] Targeting Glial Cells to Elucidate the Pathogenesis of Huntington's Disease
    Hsiao, Han-Yun
    Chern, Yijuang
    MOLECULAR NEUROBIOLOGY, 2010, 41 (2-3) : 248 - 255